{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:41:54Z","timestamp":1791088914732,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.atherosclerosis.2010.03.019","type":"journal-article","created":{"date-parts":[[2010,3,26]],"date-time":"2010-03-26T14:29:16Z","timestamp":1269613756000},"page":"367-376","source":"Crossref","is-referenced-by-count":54,"title":["Diabetes and the platelet: Toward new therapeutic paradigms for diabetic atherothrombosis"],"prefix":"10.1016","volume":"212","author":[{"given":"Olivier","family":"Morel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bareiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/00003495-200767070-00005","article-title":"Approaches to prevention of cardiovascular complications and events in diabetes mellitus","volume":"67","author":"Coccheri","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib3","first-page":"581","article-title":"Is tight glycemic control in type 2 diabetes really worthwhile? No","volume":"55","author":"Wilson","year":"2009","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib4","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.2337\/diacare.26.2007.S25","article-title":"Implications of the diabetes control and complications trial","volume":"26","author":"American Diabetes Association","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib5","first-page":"S27","article-title":"Implications of the United Kingdom Prospective Diabetes Study","volume":"23","author":"American Diabetes Association","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib6","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jacc.2005.02.047","article-title":"Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease","volume":"45","author":"Koga","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1160\/TH03-05-0294","article-title":"Sustained elevated amounts of circulating procoagulant membrane microparticles and soluble GPV after acute myocardial infarction in diabetes mellitus","volume":"91","author":"Morel","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib8","first-page":"327","article-title":"Willebrand factor in diabetic angiopathy","volume":"24","author":"Kessler","year":"1998","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11892-007-0035-1","article-title":"Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation","volume":"7","author":"Boden","year":"2007","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/MED.0b013e32807f2ad9","article-title":"Antiplatelet therapy in type 2 diabetes mellitus","volume":"14","author":"Angiolillo","year":"2007","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib11","first-page":"264","article-title":"Platelets and antiplatelet therapy in patients with diabetes mellitus","volume":"15","author":"Arjomand","year":"2003","journal-title":"J Invas Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/1573399052952631","article-title":"Advanced glycation end products (AGEs) and diabetic vascular complications","volume":"1","author":"Yamagishi","year":"2005","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2362.1997.710624.x","article-title":"Advanced glycation end products, oxidant stress and vascular lesions","volume":"27","author":"Chappey","year":"1997","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib14","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","article-title":"Diabetes and atherosclerosis: epidemiology, pathophysiology, and management","volume":"287","author":"Beckman","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib15","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2337\/diabetes.34.10.951","article-title":"Platelet glutathione and thromboxane synthesis in diabetes","volume":"34","author":"Thomas","year":"1985","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib16","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJM199006213222503","article-title":"Thromboxane biosynthesis and platelet function in type II diabetes mellitus","volume":"322","author":"Dav\u00ec","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib17","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1007\/s00125-003-1219-0","article-title":"Nitric oxide generation mediated by \u03b2-adrenoceptors is impaired in platelets from patients with Type 2 diabetes mellitus","volume":"46","author":"Queen","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib18","doi-asserted-by":"crossref","first-page":"1480H","DOI":"10.1152\/ajpheart.2001.280.4.H1480","article-title":"Platelet hyperactivity and abnormal Ca2+ hemostasis in diabetes mellitus","volume":"280","author":"Li","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1358\/dnp.2006.19.5.985936","article-title":"ADP receptors: inhibitory strategies for antiplatelet therapy","volume":"19","author":"Cattaneo","year":"2006","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1210\/jc.2004-0137","article-title":"P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes","volume":"90","author":"Matsuno","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1160\/TH08-08-0521","article-title":"Cell-derived microparticles in haemostasis and vascular medicine","volume":"101","author":"Burnier","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib22","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S0049-3848(08)70020-3","article-title":"Microparticles in vascular diseases","volume":"122","author":"George","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/09537100701817232","article-title":"Platelet microparticles and vascular cells interactions: a checkpoint between the haemostatic and thrombotic responses","volume":"19","author":"Morel","year":"2008","journal-title":"Platelets"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib24","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1084\/jem.20061302","article-title":"Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets","volume":"203","author":"Schwertz","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib25","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2796.2008.01957.x","article-title":"Role of microparticles in atherothrombosis","volume":"263","author":"Leroyer","year":"2008","journal-title":"J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-3083.2007.01984.x","article-title":"The role of microparticles in inflammation and thrombosis","volume":"66","author":"Ardoin","year":"2007","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0021-9150(95)05551-7","article-title":"Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus","volume":"116","author":"Nomura","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib28","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1161\/01.CIR.0000036596.59665.C6","article-title":"Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus","volume":"106","author":"Diamant","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1160\/TH07-11-0668","article-title":"Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome","volume":"100","author":"Ueba","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib30","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1093\/eurheartj\/ehl295","article-title":"Aspirin and clopidogrel resistance in patients with diabetes mellitus","volume":"27","author":"Scheen","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib31","doi-asserted-by":"crossref","first-page":"784.e1","DOI":"10.1016\/j.ahj.2009.08.013","article-title":"The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy","volume":"158","author":"Singla","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1160\/TH04-07-0453","article-title":"Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin","volume":"93","author":"Evangelista","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib33","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.2337\/diabetes.54.8.2430","article-title":"Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment","volume":"54","author":"Angiolillo","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib34","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib35","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1093\/eurheartj\/ehn287","article-title":"A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study","volume":"29","author":"Angiolillo","year":"2008","journal-title":"Eur Heart J"},{"issue":"November","key":"10.1016\/j.atherosclerosis.2010.03.019_bib36","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4070\/kcj.2009.39.11.462","article-title":"Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double anti-platelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation","volume":"39","author":"Yang","year":"2009","journal-title":"Kor Circ J"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib37","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jacc.2008.12.025","article-title":"Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study","volume":"53","author":"Jeong","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians\u2019 Health Study","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib39","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib40","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.2337\/diacare.26.12.3264","article-title":"Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Results of the Primary Prevention Project trial","volume":"26","author":"Sacco","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib41","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.beem.2008.12.001","article-title":"Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus","volume":"23","author":"Angiolillo","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib42","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.268.10.1292","article-title":"Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. ETDRS Investigators","volume":"268","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib43","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib44","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib45","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/eurheartj\/ehm274","article-title":"An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial","volume":"28","author":"Wang","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2840-3-1","article-title":"Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation","volume":"3","author":"Hayden","year":"2004","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib47","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9149(02)02567-5","article-title":"Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus","volume":"90","author":"Bhatt","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib49","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib50","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jacc.2003.04.004","article-title":"Short- and long-term results after multivessel stenting in diabetic patients","volume":"43","author":"Mehran","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib51","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","article-title":"Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study","volume":"369","author":"Daemen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib52","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0735-1097(99)00650-6","article-title":"Abciximab reduces mortality in diabetics following percutaneous coronary intervention","volume":"35","author":"Bhatt","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib53","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1161\/01.CIR.0000148956.93631.4D","article-title":"Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel","volume":"110","author":"Mehilli","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2459\/JCM.0b013e32832180d9","article-title":"Glycoprotein IIB\/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the \u2018OPTIMIZE-IT\u2019 pilot randomized study","volume":"10","author":"Talarico","year":"2009","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib55","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib56","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","article-title":"Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib57","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ahj.2009.01.006","article-title":"Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study","volume":"157","author":"Han","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib58","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2337\/diabetes.55.03.06.db05-1394","article-title":"Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease","volume":"55","author":"Angiolillo","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib59","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1161\/01.ATV.0000246775.14471.26","article-title":"Procoagulant microparticles: disrupting the vascular homeostasis equation?","volume":"26","author":"Morel","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib60","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1189\/jlb.0405193","article-title":"Leukocyte-versus microparticle-mediated tissue factor transfer during arteriolar thrombus development","volume":"78","author":"Gross","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib61","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1084\/jem.20082297","article-title":"Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo","volume":"206","author":"Thomas","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib62","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/nm899","article-title":"Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A","volume":"9","author":"Hrachovinov\u00e1","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib63","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1182\/blood-2004-03-0935","article-title":"Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation","volume":"104","author":"Chou","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib64","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1160\/TH08-09-0620","article-title":"Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis","volume":"101","author":"Ramacciotti","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib65","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.thromres.2009.06.033","article-title":"Cardiovascular complications of diabetes mellitus: the tissue factor perspective","volume":"125","author":"Bogdanov","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib66","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1161\/01.ATV.17.11.2885","article-title":"Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Role of oxidant stress and protein tyrosine kinase activation","volume":"17","author":"Khechai","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib67","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0021-9150(97)00221-9","article-title":"Advanced glycosylation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients","volume":"136","author":"Ichikawa","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib68","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/09537100600760814","article-title":"Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects","volume":"17","author":"Vaidyula","year":"2006","journal-title":"Platelets"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib69","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.2337\/diabetes.51.9.2840","article-title":"Type 1 and type 2 diabetic patients display different patterns of cellular microparticles","volume":"51","author":"Sabatier","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib70","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2337\/diabetes.54.6.1755","article-title":"Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation","volume":"54","author":"Johansson","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib71","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.mvr.2008.07.007","article-title":"Tissue factor-containing microparticles released from mesangial cells in response to high glucose and AGE induce tube formation in microvascular cells","volume":"76","author":"Ettelaie","year":"2008","journal-title":"Microvasc Res"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib72","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/09537100903114545","article-title":"Correlation and association between plasma platelet-, monocyte- and endothelial cell-derived microparticles in hypertensive patients with type 2 diabetes mellitus","volume":"20","author":"Nomura","year":"2009","journal-title":"Platelets"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib73","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1111\/j.1440-1681.2009.05219.x","article-title":"Decreased mobilization of endothelial progenitor cells contributes to impaired neovascularization in diabetes","volume":"36","author":"Kang","year":"2009","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib74","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.atherosclerosis.2007.07.012","article-title":"Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk","volume":"197","author":"Pirro","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib75","article-title":"Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus","author":"Feng","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib76","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.atherosclerosis.2008.07.039","article-title":"Increased levels of endothelial microparticles CD144 (VE-Cadherin) positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by multidetector computed tomography (MDCT)","volume":"203","author":"Bernard","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib77","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jacc.2009.05.022","article-title":"Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease","volume":"54","author":"Nozaki","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib78","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1262-3636(08)70100-9","article-title":"Microparticles and type 2 diabetes","volume":"34","author":"Leroyer","year":"2008","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib79","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/9780470985571.ch9","article-title":"The impact of insulin resistance on macrophage death pathways in advanced atherosclerosis","volume":"286","author":"Tabas","year":"2007","journal-title":"Novartis Found Symp"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib80","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/blood.V99.8.2794","article-title":"Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque","volume":"99","author":"Bonderman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib81","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.atherosclerosis.2008.10.039","article-title":"Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation","volume":"204","author":"Morel","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib82","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-9560-7-11","article-title":"Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction","volume":"7","author":"Steppich","year":"2009","journal-title":"Thromb J"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib83","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1538-7836.2008.03206.x","article-title":"Insulin inhibits tissue factor expression in monocytes","volume":"7","author":"Gerrits","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib84","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbrc.2004.05.127","article-title":"Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway","volume":"320","author":"Tramontano","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib85","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/j.1538-7836.2005.01403.x","article-title":"Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes","volume":"3","author":"Sommeijer","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib86","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/09537100802409921","article-title":"The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients","volume":"20","author":"Nomura","year":"2009","journal-title":"Platelets"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib87","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.atherosclerosis.2006.07.031","article-title":"Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes","volume":"194","author":"Koh","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib88","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1160\/TH07-12-0760","article-title":"Simvastatin-induced endothelial cell detachment and microparticle release are prenylation dependent","volume":"100","author":"Diamant","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib89","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1538-7836.2003.00010.x","article-title":"Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles","volume":"1","author":"Morel","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.atherosclerosis.2010.03.019_bib90","doi-asserted-by":"crossref","DOI":"10.5551\/jat.2642","article-title":"Assessment of an ELISA kit for platelet-derived microparticles by joint research at many institutes in Japan","author":"Nomura","year":"2009","journal-title":"J Atheroscler Thromb"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915010002352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915010002352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T06:31:51Z","timestamp":1635143511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915010002352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0021915010002352"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2010.03.019","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}